ATE400274T1 - Hemmstoffe der akt aktivität - Google Patents

Hemmstoffe der akt aktivität

Info

Publication number
ATE400274T1
ATE400274T1 AT02721697T AT02721697T ATE400274T1 AT E400274 T1 ATE400274 T1 AT E400274T1 AT 02721697 T AT02721697 T AT 02721697T AT 02721697 T AT02721697 T AT 02721697T AT E400274 T1 ATE400274 T1 AT E400274T1
Authority
AT
Austria
Prior art keywords
compounds
activity inhibitors
act activity
act
directed
Prior art date
Application number
AT02721697T
Other languages
English (en)
Inventor
Stanley Barnett
Samuel Graham
David Remy
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE400274T1 publication Critical patent/ATE400274T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Seeds, Soups, And Other Foods (AREA)
AT02721697T 2001-04-10 2002-04-08 Hemmstoffe der akt aktivität ATE400274T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28278101P 2001-04-10 2001-04-10

Publications (1)

Publication Number Publication Date
ATE400274T1 true ATE400274T1 (de) 2008-07-15

Family

ID=23083087

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02721697T ATE400274T1 (de) 2001-04-10 2002-04-08 Hemmstoffe der akt aktivität

Country Status (8)

Country Link
US (1) US7034026B2 (de)
EP (1) EP1379251B1 (de)
JP (1) JP4361276B2 (de)
AT (1) ATE400274T1 (de)
AU (1) AU2002252614B2 (de)
CA (1) CA2442270C (de)
DE (1) DE60227492D1 (de)
WO (1) WO2002083138A1 (de)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL144583A0 (en) * 2001-07-26 2002-05-23 Peptor Ltd Chimeric protein kinase inhibitors
CA2480800C (en) * 2002-04-08 2008-09-23 Mark T. Bilodeau Inhibitors of akt activity
JP4451136B2 (ja) * 2002-04-08 2010-04-14 メルク エンド カムパニー インコーポレーテッド Akt活性阻害薬
AU2003284981B2 (en) * 2002-10-30 2009-05-28 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
CN102386330B (zh) 2003-04-18 2014-10-22 株式会社半导体能源研究所 喹喔啉衍生物以及使用它的有机半导体元件、电致发光元件以及电子仪器
US7414055B2 (en) 2003-04-24 2008-08-19 Merck & Co., Inc. Inhibitors of Akt activity
AU2004233827B2 (en) 2003-04-24 2009-05-28 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
DE602004026047D1 (de) * 2003-04-24 2010-04-29 Merck Sharp & Dohme Hemmer der akt aktivität
AU2004233828B2 (en) 2003-04-24 2009-05-28 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
IL156429A0 (en) * 2003-06-12 2004-01-04 Peptor Ltd Cell permeable conjugates of peptides for inhibition of protein kinases
CN1942470A (zh) * 2004-04-09 2007-04-04 默克公司 Akt活性抑制剂
CA2561311A1 (en) * 2004-04-09 2005-10-27 Merck & Co., Inc. Inhibitors of akt activity
US7544677B2 (en) * 2004-08-23 2009-06-09 Merck & Co., Inc. Inhibitors of Akt activity
JP2008524339A (ja) 2004-12-15 2008-07-10 メルク エンド カムパニー インコーポレーテッド Akt活性のインヒビター
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
WO2006135627A2 (en) 2005-06-10 2006-12-21 Merck & Co., Inc. Inhibitors of akt activity
PE20070335A1 (es) 2005-08-30 2007-04-21 Novartis Ag Benzimidazoles sustituidos y metodos para su preparacion
KR101540037B1 (ko) * 2005-09-12 2015-07-29 가부시키가이샤 한도오따이 에네루기 켄큐쇼 퀴녹살린 유도체, 및 퀴녹살린 유도체를 사용한 발광소자, 발광장치, 전자 기기
WO2007087246A2 (en) 2006-01-24 2007-08-02 Merck & Co., Inc. Jak2 tyrosine kinase inhibition
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2004616B1 (de) * 2006-03-21 2014-05-21 Semiconductor Energy Laboratory Co., Ltd. Chinoxalinderivat und lichtemittierendes element, lichtemittierendes gerät, elektronisches gerät, bei dem das chinoxalinderivat verwendet wird
KR101464385B1 (ko) 2006-04-19 2014-11-21 노파르티스 아게 6-o-치환된 벤즈옥사졸 및 벤조티아졸 화합물, 및 csf-1r 신호전달의 억제 방법
AU2007300627B2 (en) 2006-09-22 2012-02-16 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
EP2120951A4 (de) * 2006-12-06 2012-02-15 Merck Sharp & Dohme Hemmer der akt-aktivität
AR064010A1 (es) * 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
PT2099442E (pt) 2006-12-26 2015-02-10 Pharmacyclics Inc Métodos de utilização de inibidores de histona desacetilase e monitorização de biomarcadores em terapia de combinação
BRPI0806245B1 (pt) 2007-01-10 2022-01-25 Msd Italia S.R.L. Compostos de fórmula i e seus usos
US8178216B2 (en) * 2007-02-28 2012-05-15 Semiconductor Energy Laboratory Co., Ltd. Quinoxaline derivative, and light-emitting element, light-emitting device, and electronic device including quinoxaline derivative
CN101679266B (zh) 2007-03-01 2015-05-06 诺华股份有限公司 Pim激酶抑制剂及其应用方法
AU2008254425A1 (en) 2007-05-21 2008-11-27 Novartis Ag CSF-1R inhibitors, compositions, and methods of use
AR066879A1 (es) * 2007-06-08 2009-09-16 Novartis Ag Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
WO2009002495A1 (en) 2007-06-27 2008-12-31 Merck & Co., Inc. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
EP2067778B1 (de) * 2007-12-03 2016-08-17 Semiconductor Energy Laboratory Co., Ltd. Quinoxalin-Derivat und lichtemittierendes Element, lichtemittierende Vorrichtung und elektronische Vorrichtung damit
JP5574598B2 (ja) * 2007-12-03 2014-08-20 株式会社半導体エネルギー研究所 キノキサリン誘導体、およびキノキサリン誘導体を用いた発光素子、発光装置、電子機器
US8207169B2 (en) * 2008-06-03 2012-06-26 Msd K.K. Substituted [1,2,4]triazolo[4′,3′:1,6]pyrido[2,3-b]pyrazines of the formula D
JP2011522047A (ja) * 2008-06-03 2011-07-28 メルク・シャープ・エンド・ドーム・コーポレイション Akt活性の阻害剤
WO2010088177A1 (en) * 2009-02-02 2010-08-05 Merck Sharp & Dohme Corp. Inhibitors of akt activity
EP2396004A4 (de) * 2009-02-11 2012-07-25 Reaction Biology Corp Selektive kinasehemmer
WO2010104705A1 (en) 2009-03-12 2010-09-16 Merck Sharp & Dohme Corp. Inhibitors of akt activity
EP2413932A4 (de) 2009-04-01 2012-09-19 Merck Sharp & Dohme Hemmer der akt-aktivität
CA2777043C (en) 2009-10-14 2015-12-15 Schering Corporation Substituted piperidines that increase p53 activity and the uses thereof
AU2010331927B2 (en) 2009-12-17 2013-10-10 Merck Canada Inc. Aminopyrimidines as Syk inhibitors
EP2584903B1 (de) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Neue heterozyklische verbindungen als erk-hemmer
CN103068980B (zh) 2010-08-02 2017-04-05 瑟纳治疗公司 使用短干扰核酸(siNA)的RNA干扰介导的联蛋白(钙粘蛋白关联蛋白质),β1(CTNNB1)基因表达的抑制
RU2745848C2 (ru) 2010-08-17 2021-04-01 Сирна Терапьютикс, Инк. ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (de) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazolderivate als erk-hemmer
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
WO2012143879A1 (en) 2011-04-21 2012-10-26 Piramal Healthcare Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
EP2548877A1 (de) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Gliedrige kondensierte Pyridinyl)benzamide als BTK-Inhibitoren
WO2013032951A1 (en) 2011-08-26 2013-03-07 Neupharma, Inc. Certain chemical entities, compositions, and methods
AU2012308238B2 (en) 2011-09-14 2017-05-25 Neupharma, Inc. Certain chemical entities, compositions, and methods
US9249110B2 (en) 2011-09-21 2016-02-02 Neupharma, Inc. Substituted quinoxalines as B-raf kinase inhibitors
WO2013049701A1 (en) 2011-09-30 2013-04-04 Neupharma, Inc. Certain chemical entities, compositions, and methods
EP2770987B1 (de) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Neue verbindungen als erk-hemmer
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
EP2806874B1 (de) 2012-01-25 2017-11-15 Neupharma, Inc. Quinoxalin-oxy-phenyl derivate als Kinase-Inhibitoren
EP3919620A1 (de) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Zusammensetzungen mit kurzer interferierender nukleinsäure (sina)
US9376418B2 (en) 2012-06-22 2016-06-28 Merck Sharp & Dohme Corp. Substituted pyridine spleen tyrosine kinase (SYK) inhibitors
WO2013192088A1 (en) 2012-06-22 2013-12-27 Merck Sharp & Dohme Corp. SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS
CN104812389B (zh) 2012-09-24 2020-07-17 润新生物公司 某些化学实体、组合物及方法
CA2882950A1 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
US9725421B2 (en) 2012-11-12 2017-08-08 Neupharma, Inc. Substituted quinoxalines as B-raf kinase inhibitors
SMT201700595T1 (it) 2012-11-28 2018-03-08 Merck Sharp & Dohme Composizioni e metodi per trattare il cancro
WO2014100065A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
WO2014113942A1 (en) 2013-01-23 2014-07-31 Merck Sharp & Dohme Corp. Btk inhibitors
US9481682B2 (en) 2013-01-23 2016-11-01 Merck Sharp & Dohme Corp. Substituted benzamides and substituted pyridinecarboxamides as Btk inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
EP2953939A1 (de) 2013-02-07 2015-12-16 Merck Patent GmbH Substituierte chinoxalinderivate und deren verwendung als positive allosterische modulatoren von mglur4
WO2014176216A1 (en) 2013-04-26 2014-10-30 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
US9670196B2 (en) 2013-12-20 2017-06-06 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as Spleen Tyrosine Kinase inhibitors
US9834554B2 (en) 2013-12-20 2017-12-05 Merck Sharp & Dohme Corp. BTK inhibitors
US9637486B2 (en) 2013-12-20 2017-05-02 Merck Sharp & Dohme Corp. Btk inhibitors
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
WO2016106623A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Benzamide imidazopyrazine btk inhibitors
WO2016106626A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Imidazopyrazine analogs with 3-tertiary carbon substitutions as btk inhibitors
WO2016106629A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Btk inhibitors
WO2016106624A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Tertiary alcohol imidazopyrazine btk inhibitors
WO2016106628A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Btk inhibitors
CN108472298B (zh) 2015-11-24 2021-04-20 深圳阿拉丁医疗科技有限公司 选择性激酶抑制剂
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
JP7160833B2 (ja) 2017-04-13 2022-10-25 サイロパ ビー.ブイ. 抗sirpアルファ抗体
WO2019094312A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3706742B1 (de) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5-inhibitoren
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
WO2020007234A1 (zh) 2018-07-02 2020-01-09 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的炔基(杂)芳环类化合物
US11746110B2 (en) 2018-07-17 2023-09-05 Shenzhen Targetrx, Inc. Alkynyl (hetero) aromatic ring compounds used for inhibiting protein kinase activity
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033285A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
CA3108388A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833667B1 (de) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5-inhibitoren
CN109518211B (zh) * 2019-01-08 2020-11-06 合肥工业大学 一种芳香偶酰类化合物的电化学合成方法
EP4076460B1 (de) 2019-12-17 2026-01-21 Merck Sharp & Dohme LLC 1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidin]-derivate als prmt5 inhibitoren zur behandlung von krebs
EP4076459B1 (de) 2019-12-17 2026-04-29 Merck Sharp & Dohme LLC Prmt5-inhibitoren
ES3022307T3 (en) 2019-12-17 2025-05-28 Merck Sharp & Dohme Llc Prmt5 inhibitors
ES3074517T3 (en) 2019-12-17 2026-07-21 Merck Sharp & Dohme Llc 4-(3,4-dihydroisoquinolin-2(1h)-yl)-3-hydroxypiperidine derivatives as prmt5 inhibitors for the treatment of cancer and sickle cell disease
DE212025000115U1 (de) 2024-07-30 2026-06-18 Sairopa B.V. Anti-SIRP Alpha-Antikörperformulierungen und ihre Verwendung

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1384713A (fr) * 1962-11-24 1965-01-08 Kalle Ag Matériel d'électrophotographie
NL300539A (de) * 1962-11-24
DE3420039A1 (de) 1984-05-29 1985-12-12 Hoechst Ag, 6230 Frankfurt 2,3-bis(dialkylaminophenyl)chinoxaline und ihre verwendung in elektrophotographischen aufzeichnungsmaterialien
IN166761B (de) 1987-04-10 1990-07-14 Hoechst India
JPS6457261A (en) * 1987-08-28 1989-03-03 Alps Electric Co Ltd Photoconductive film and electrophotographic sensitive body using same
EP0397859A4 (en) 1987-11-12 1990-12-19 Terumo Kabushiki Kaisha Pyrazine derivatives and medicinal preparation containing same
GB2293380A (en) 1994-09-22 1996-03-27 Zeneca Ltd Pesticidal heterocyclic and phenyl compounds
US6060491A (en) 1997-06-19 2000-05-09 Dupont Pharmaceuticals 6-membered aromatics as factor Xa inhibitors
AU1918299A (en) 1998-02-23 1999-09-06 Warner-Lambert Company Substituted quinoxaline derivatives as interleukin-8 receptor antagonists
JP2000309578A (ja) 1999-04-27 2000-11-07 Kyowa Hakko Kogyo Co Ltd キノキサリン誘導体
BR0116493A (pt) 2000-12-21 2003-09-30 Vertex Pharma Compostos de pirazol úteis como inibidores de proteìna cinase
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors

Also Published As

Publication number Publication date
AU2002252614B2 (en) 2006-09-14
EP1379251A4 (de) 2005-05-25
US7034026B2 (en) 2006-04-25
DE60227492D1 (de) 2008-08-21
EP1379251A1 (de) 2004-01-14
JP2004525961A (ja) 2004-08-26
JP4361276B2 (ja) 2009-11-11
US20040143117A1 (en) 2004-07-22
EP1379251B1 (de) 2008-07-09
CA2442270A1 (en) 2002-10-24
WO2002083138A1 (en) 2002-10-24
CA2442270C (en) 2009-09-08

Similar Documents

Publication Publication Date Title
DE60227492D1 (de) Hemmstoffe der akt aktivität
EP1631548A4 (de) Hemmer der akt aktivität
CA2480800A1 (en) Inhibitors of akt activity
EP1622616A4 (de) Hemmer der akt aktivität
EP1620411A4 (de) Hemmer der akt aktivität
WO2003086279A3 (en) Inhibitors of akt activity
EP1558586A4 (de) Hemmer der akt aktivität
EP1737843A4 (de) Hemmer der akt aktivität
WO2006036395A3 (en) Inhibitors of akt activity
WO2004096130A3 (en) Inhibitors of akt activity
YU84603A (sh) Novi inhibitori tirozin kinaze
MXPA03010961A (es) Compuestos de tiazol utiles como inhibidores de proteinas cinasas.
WO2002083675A3 (en) Inhibitors of akt activity
DE60214703D1 (de) Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
BG106585A (en) Kinase inhibitors as therapeutic agents
MY141739A (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
HRP20000469B1 (hr) Biciklički heteroaromatični spojevi kao inhibitori protein -tirozin kinaze
MXPA03010207A (es) Nuevas 4-anilinoquinolin-3-carboxamidas.
ATE437872T1 (de) Proteinkinaseinhibitoren
BG106020A (en) Inhibitors of impdh enzyme
PT652868E (pt) Inibidores da fosfodiesterase do amp ciclico
NO20034204D0 (no) Farmasöytiske kombinasjoner til behandling av kreft
PA8509301A1 (es) Inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en enfermedades inflamatorias, autoinmunes y respiratorias
EA200400475A1 (ru) Замещенные производные бензимидазола и их применение для лечения злокачественной опухоли
MXPA04005809A (es) Inhibidores de proteinas quinasas.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties